Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kevin Boyce

Physician Assistant Ripley, WV Physician Assistant

NPI 1073577987 CMS profile 10506408

122 Pinnell St, Ripley, WV 25271

Open in the dashboard

General payments

$1,677

100 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Boyce of Ripley, WV is reported in the CMS Open Payments database as having received $1,677 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $547 30
2024 General $212 13
2023 General $419 25
2022 General $448 29
2021 General $50 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Boyce
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kevin Boyce were reported at $547. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kevin Boyce Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $50 $132 $37–$438 $132
2022 $448 $155 $48–$522 $149
2023 $419 $167 $52–$557 $160
2024 $212 $178 $55–$600 $164
2025 $547 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $500 36 payments
  2. Abbott Laboratories $239 13 payments
  3. Pfizer Inc. $235 16 payments
  4. AbbVie, Inc. $183 8 payments
  5. Exact Sciences Corporation $90 5 payments
  6. Novartis Pharmaceuticals Corporation $60 3 payments
  7. ITI, Inc. $52 2 payments
  8. Vertex Pharmaceuticals Incorporated $49 2 payments
  9. GlaxoSmithKline, LLC. $47 3 payments
  10. Lundbeck LLC $42 2 payments
  11. Other $178 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,677 100 payments
Products named General payments · program years 2021–2025
  1. Ozempic $302 24 payments
  2. RYBELSUS $289 23 payments
  3. ELIQUIS $212 14 payments
  4. NURTEC ODT $208 14 payments
  5. FreeStyle Libre 2 $170 9 payments
  6. UBRELVY $142 6 payments
  7. QULIPTA $122 6 payments
  8. Cologuard Collection Kit $90 5 payments
  9. Wegovy $84 5 payments
  10. LEQVIO $60 3 payments
  11. Other $526 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

4,953

Median for Physician Assistant: 241

Drug cost

$328,520

Median for Physician Assistant: $4,110

Branded share of claims

21%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 54 $51,808
Ozempic Semaglutide Brand 41 $44,397
Januvia Sitagliptin Phosphate Brand 41 $32,635
Jardiance Empagliflozin Brand 23 $30,708
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 37 $30,212
Farxiga Dapagliflozin Propanediol Brand 20 $27,883
Tresiba Flextouch U-100 Insulin Degludec Brand 37 $18,377
Rexulti Brexpiprazole Brand 12 $17,795
Symbicort Budesonide/Formoterol Fumarate Brand 23 $9,076
Breo Ellipta Fluticasone/Vilanterol Brand 15 $8,256

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $43
$43 — —
REXULTI
  • Lundbeck LLC $17
$17 12 —
UBRELVY
  • AbbVie, Inc. $17
$17 — —
QULIPTA
  • AbbVie, Inc. $17
$17 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $15
$15 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record